Drug Profile
Fosfomycin intravenous - Nabriva Therapeutics
Alternative Names: CONTEPO; Fosfomycin disodium; Fosfomycin for injection - Nabriva Therapeutics; IV fosfomycin - Nabriva Therapeutics; ZOLYD; ZTI-01Latest Information Update: 15 May 2023
Price :
$50
*
At a glance
- Originator Zavante Therapeutics
- Developer Nabriva Therapeutics; National Institute of Allergy and Infectious Diseases; Zavante Therapeutics
- Class Anti-infectives; Antibacterials; Epoxy compounds; Organophosphorus compounds; Phosphonic acids; Phosphoric acid esters; Small molecules
- Mechanism of Action Cell wall inhibitors; Peptidoglycan inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Urinary tract infections
- Phase II Intra-abdominal infections; Skin and soft tissue infections
- No development reported Bacterial infections; Gram-negative infections; Nosocomial infections
Most Recent Events
- 31 Dec 2022 Nabvira Therapeutics has patent protection for Fosfomycin intravenous in USA, prior to December 2022
- 31 Dec 2022 Discontinued - Phase-I for Urinary tract infections (In children, In infants, In neonates, Complicated) in USA (IV), prior to December 2022
- 22 Nov 2022 Chemical structure information added